GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

The company's innovative new product lineup and expansive list of patent-protected drugs create a wide economic moat, in our opinion. Wide-moat GSK’s third-quarter earnings aligned with our ...

and robust product delivery practices, including building supply capacity. The drugmaker's chief executive, Emma Walmsley noted this is the eighth time that GSK had headed the list, and comes ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

GSK lands on Morningstar’s Best Companies to Own list for 2024. It’s also one of ... the company from problems with any single product. Additionally, GSK has developed next-generation drugs ...

The Nigerian economy has seen the closure of many companies, especially multinational firms, which threw many Nigerians into ...

In weakly acid conditions, lipid A can be hydrolyzed to obtain monophosphoryl lipid A (MPL® [GSK and other]), a compound which retains the adjuvant activity of lipid A with reduced toxicity.

Given the lack of innovation and over-reliance on existing products, I recommend a "sell" rating for Haleon, questioning its standalone success and justification for current valuation. GSK chose ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... and data readouts supporting future product momentum. So far this year ...